Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
Xinxing DuYanhao DongJiazhou LiuYun SuYinjie ZhuJiahua PanBaijun DongRuohua ChenJianjun LiuZhen TongKenneth J PientaSteven P RoweLiang DongWei XuePublished in: The Prostate (2023)
This study further highlights the accuracy and necessity of PSMA-PET/CT in newly diagnosed, high-risk, nonmetastatic PCa patients.